Dendritic cell immunotherapy: clinical outcomes

Clinical and Translational Immunology

Volumn 3, Issue 7, 2014, Pages

  Apostolopoulos, Vasso ^a   Pietersz, Geoffrey A ^b,c,d   Tsibanis, Anastasios ^e   Tsikkinis, Annivas ^e   Stojanovska, Lily ^a   McKenzie, Ian FC ^c   Vassilaros, Stamatis ^e  

^a VICTORIA UNIVERSITY   (Australia)

^b BURNET INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e Prolipsis Breast Diagnostic Center   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84947267445     PISSN: None     EISSN: 20500068     Source Type: Journal    
DOI: 10.1038/cti.2014.14     Document Type: Review

References (43)

1. Wilson NS, Villadangos JA. Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications. Adv Immunol 2005; 86: 241–305.
2. Apostolopoulos V, Thalhammer T, Tzakos AG, Stojanovska L. Targeting antigens to dendritic cell receptors for vaccine development. J Drug Delivery 2013; 2013: 869718.
3. Apostolopoulos V, Barnes N, Pietersz GA, McKenzie IF. Ex vivo targeting of the macrophage mannose receptor generates anti- tumor CTL responses. Vaccine 2000; 18: 3174–3184.
4. Apostolopoulos V, McKenzie IF. Role of the mannose receptor in the immune response. Curr Mol Med 2001; 1: 469–474.
5. Apostolopoulos V, Pietersz GA, Gordon S, Martinez-Pomares L, McKenzie IF. Aldehyde-mannan antigen complexes target the MHC class I antigen- presentation pathway. Eur J Immunol 2000; 30: 1714–1723.
6. Apostolopoulos V, Pietersz GA, Loveland BE, Sandrin MS, McKenzie IF. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci USA 1995; 92: 10128–10132.
7. Apostolopoulos V, Pietersz GA, McKenzie IF. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 1996; 14: 930–938.
8. Tan MC, Mommaas AM, Drijfhout JW, Jordens R, Onderwater JJ, Verwoerd D et al. Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells. Eur J Immunol 1997; 27: 2426–2435.
9. Sheng KC, Pouniotis DS, Wright MD, Tang CK, Lazoura E, Pietersz GA et al. Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology 2006; 118: 372–383.
10. Sheng KC, Kalkanidis M, Pouniotis DS, Esparon S, Tang CK, Apostolopoulos V et al. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur J Immunol 2008; 38: 424–436.
11. Sheng KC, Kalkanidis M, Pouniotis DS, Wright MD, Pietersz GA, Apostolopoulos V. The adjuvanticity of a mannosylated antigen reveals TLR4 functionality essential for subset specialization and functional maturation of mouse dendritic cells. J Immunol 2008; 181: 2455–2464.
12. Tang CK, Sheng KC, Esparon SE, Proudfoot O, Apostolopoulos V, Pietersz GA. Molecular basis of improved immunogenicity in DNA vaccination mediated by a mannan based carrier. Biomaterials 2009; 30: 1389–1400.
13. Tang CK, Sheng KC, Pouniotis D, Esparon S, Son HY, Kim CW et al. Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses. Vaccine 2008; 26: 3827–3834.
14. Cui Z, Hsu CH, Mumper RJ. Physical characterization and macrophage cell uptake of mannan-coated nanoparticles. Drug Dev Industrial Pharm 2003; 29: 689–700.
15. Toda S, Ishii N, Okada E, Kusakabe KI, Arai H, Hamajima K et al. HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-gamma antibody. Immunology 1997; 92: 111–117.
16. Foged C, Arigita C, Sundblad A, Jiskoot W, Storm G, Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 2004; 22: 1903–1913.
17. Thomann JS, Heurtault B, Weidner S, Brayé M, Beyrath J, Fournel S et al. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting. Biomaterials 2011; 32: 4574–4583.
18. Espuelas S, Thumann C, Heurtault B, Schuber F, Frisch B. Influence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes. Bioconj Chem 2008; 19: 2385–2393.
19. Hamdy S, Haddadi A, Shayeganpour A, Samuel J, Lavasanifar A. Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles. Pharm Res 2011; 28: 2288–2301.
20. Jiang HL, Kang ML, Quan JS, Kang SG, Akaike T, Yoo HS et al. The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization. Biomaterials 2008; 29: 1931–1939.
21. Shiku H, Wang L, Ikuta Y, Okugawa T, Schmitt M, Gu X et al. Development of a cancer vaccine: peptides, proteins, and DNA. Cancer Chemother Pharm 2000; 46 (Suppl): S77–S82.
22. Moyle PM, Olive C, Ho MF, Pandey M, Dyer J, Suhrbier A et al. Toward the development of prophylactic and therapeutic human papillomavirus type-16 lipopeptide vaccines. J Med Chem 2007; 50: 4721–4727.
23. Presicce P, Taddeo A, Conti A, Villa ML, Della Bella S. Keyhole limpet hemocyanin induces the activation and maturation of human dendritic cells through the involvement of mannose receptor. Mol Immunol 2008; 45: 1136–1145.
24. He LZ, Ramakrishna V, Connolly JE, Wang XT, Smith PA, Jones CL et al. A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin beta. Clin Cancer Res 2004; 10: 1920–1927.
25. Ramakrishna V, Treml JF, Vitale L, Connolly JE, O'Neill T, Smith PA et al. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J Immunol 2004; 172: 2845–2852.
26. Lam JS, Huang H, Levitz SM. Effect of differential N-linked and O-linked mannosylation on recognition of fungal antigens by dendritic cells. PLoS ONE 2007; 2: e1009.
27. Ahlen G, Strindelius L, Johansson T, Nilsson A, Chatzissavidou N, Sjöblom M et al. Mannosylated mucin-type immunoglobulin fusion proteins enhance antigen-specific antibody and T lymphocyte responses. PLoS ONE 2012; 7: e46959.
28. Karanikas V, Hwang LA, Pearson J, Ong CS, Apostolopoulos V, Vaughan H et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 1997; 100: 2783–2792.
29. Karanikas V, Lodding J, Maino VC, McKenzie IF. Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy. Clin Cancer Res 2000; 6: 829–837.
30. Karanikas V, Thynne G, Mitchell P, Ong CS, Gunawardana D, Blum R et al. Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection. J Immunother 2001; 24: 172–183.
31. Apostolopoulos V, Pietersz GA, Tsibanis A, Tsikkinis A, Drakaki H, Loveland BE et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Br Cancer Res 2006; 8: R27.
32. Vassilaros S, Tsibanis A, Tsikkinis A, Pietersz GA, McKenzie IF, Apostolopoulos V. Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1. Immunotherapy 2013; 5: 1177–1182.
33. Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedl S, Lei Y et al. Dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res 2014; 20: 2433–2444.
34. Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman ZN et al. Wilms' Tumor Gene 1 (WT1)—loaded dendritic cell mmunotherapy in patients with uterine tumors: a phase I/II clinical trial. Anticancer Res 2013; 33: 5495–5500.
35. Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 2006; 12: 869–877.
36. Koski GK, Koldovsky U, Xu S, Mick R, Sharma A, Fitzpatrick E et al. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother 2012; 35: 54–65.
37. Hildenbrand B, Sauer B, Kalis O, Stoll C, Freudenberg MA, Niedermann G et al. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells—a pilot study. Prostate 2007; 67: 500–508.
38. Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von Moos R, Böhme C, Schmid HP et al. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 2006; 55: 1524–1533.
39. Qi CJ, Ning YL, Han YS, Min HY, Ye H, Zhu YL et al. Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer. Cancer Immunol Immunother 2012; 61: 1415–1424.
40. Mantia-Smaldone GM, Chu CS. A review of dendritic cell therapy for cancer: progress and challenges. BioDrugs 2013; 27: 453–468.
41. Morse MA, Chapman R, Powderly J, Blackwell K, Keler T, Green J et al. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin Cancer Res 2011; 17: 4844–4853.
42. Tsuji T, Matsuzaki J, Kelly MP, Ramakrishna V, Vitale L, He LZ et al. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity. J Immunol 2011; 186: 1218–1227.
43. Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med 2014; 6: 232ra251.